Literature DB >> 29188319

A dedicated paracentesis clinic decreases healthcare utilization for serial paracenteses in decompensated cirrhosis.

Yao-Wen Cheng1, Kumar Sandrasegaran2, Katherine Cheng3, Angela Shah2, Marwan Ghabril1, William Berry2, Craig Lammert1, Naga Chalasani1, Eric S Orman4.   

Abstract

PURPOSE: The purpose of the study is to describe the effect of a dedicated paracentesis clinic on healthcare utilization by patients with decompensated cirrhosis and refractory ascites.
METHODS: This Institutional Review Board-approved retrospective study identified cirrhotic patients receiving paracenteses over a 6-month period before and after creating the paracentesis clinic. Patients were followed for 12 months to collect outcome data including characteristics of subsequent hospitalizations and paracenteses. Logistic regression was used to examine the association between the paracentesis clinic and outcomes.
RESULTS: There were 183 patients and 1364 paracenteses performed during the study time period. Age, gender, cirrhosis etiology, MELD, Child-Pugh, and Charlson comorbidity index were comparable between the two groups. Rates of mortality, transplant, and hospitalization were also similar during 1 year follow-up. After establishment of the paracentesis clinic, median paracenteses per patient increased from 2 (IQR 1-7) to 4 (IQR 2-11) (P = 0.01); albumin replacement after paracenteses ≥ 5 L improved from 76.3% to 91.7% (P < 0.001); and the fraction of outpatient paracenteses performed in the emergency department decreased from 13.4% to 3.8% (P < 0.001). Major complications remained negligible at 0.81% across both time periods. While fewer patients were admitted for ascites after the paracentesis clinic (39.6% vs. 20.8%, P = 0.009), more patients had acute kidney injury (AKI) during follow-up (47.2% vs. 65.9%, P = 0.02), with a trend towards more AKI admissions (22.6% vs. 35.4%, P = 0.09).
CONCLUSION: A dedicated paracentesis clinic can improve access and wait times, while also reducing admissions for ascites and paracenteses performed in the emergency department.

Entities:  

Keywords:  Cirrhosis; Healthcare utilization; Hospitalizations; Paracentesis

Mesh:

Year:  2018        PMID: 29188319      PMCID: PMC5975110          DOI: 10.1007/s00261-017-1406-y

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  30 in total

1.  Management of adult patients with ascites due to cirrhosis.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

2.  Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.

Authors:  P Ginès; L Titó; V Arroyo; R Planas; J Panés; J Viver; M Torres; P Humbert; A Rimola; J Llach
Journal:  Gastroenterology       Date:  1988-06       Impact factor: 22.682

3.  The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009.

Authors:  Thomas D Boyer; Ziv J Haskal
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 4.  Human serum albumin, systemic inflammation, and cirrhosis.

Authors:  Vicente Arroyo; Rita García-Martinez; Xavier Salvatella
Journal:  J Hepatol       Date:  2014-04-18       Impact factor: 25.083

5.  Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.

Authors:  Pere Ginès; Juan Uriz; Blas Calahorra; Guadalupe Garcia-Tsao; Patrick S Kamath; Luis Ruiz Del Arbol; Ramón Planas; Jaime Bosch; Vicente Arroyo; Juan Rodés
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

Review 6.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

7.  Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.

Authors:  Mauro Bernardi; Paolo Caraceni; Roberta J Navickis; Mahlon M Wilkes
Journal:  Hepatology       Date:  2012-04       Impact factor: 17.425

8.  Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.

Authors:  Christophe Bureau; Dominique Thabut; Frédéric Oberti; Sébastien Dharancy; Nicolas Carbonell; Antoine Bouvier; Philippe Mathurin; Philippe Otal; Pauline Cabarrou; Jean Marie Péron; Jean Pierre Vinel
Journal:  Gastroenterology       Date:  2016-09-20       Impact factor: 22.682

9.  Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities.

Authors:  P A McVay; P T Toy
Journal:  Transfusion       Date:  1991-02       Impact factor: 3.157

10.  Paracentesis of ascitic fluid. A safe procedure.

Authors:  B A Runyon
Journal:  Arch Intern Med       Date:  1986-11
View more
  2 in total

1.  An Academic Hospitalist-Run Outpatient Paracentesis Clinic.

Authors:  Lawrence D Gerber; Gaetan Sgro; Jessica E Cyr; Sharon Conlin
Journal:  Fed Pract       Date:  2022-03-11

Review 2.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.